Bristol-Myers Experimental Cocktail Bests Hepatitis C Treatment | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Combination Therapy Plus Fluvastatin Improves Hep C Outcome

Back to News Homepage
Next

Telaprevir's Chemistry Speeds HCV Treatment Time

Bristol-Myers Experimental Cocktail Bests Hepatitis C Treatment

The Editors at Hepatitis Central
April 7, 2011

Print this page

Without pegylated interferon, experimental drugs by Bristol-Myers Squibb appear to be on the path of improving Hepatitis C treatment – by making it easier to endure and increasing the success rate.

Bristol-Myers Interferon-Free Combo Cured Hepatitis Patients

By Naomi Kresge – Apr 2, 2011

Bristol-Myers Squibb Co. (BMY)’s cocktail of two experimental drugs cured four hepatitis C patients in the first success for a therapy that excludes often-toxic existing drugs.

The combination had a higher rate of success when paired with the current standard treatment in the 21-person trial, curing nine of 10 patients, researchers said today at the Berlin meeting of the European Association for the Study of the Liver. The study points to the next generation of drugs for the evasive virus, said Mark Thursz, a professor of hepatology at Imperial College London and vice-secretary of EASL.

Continue reading this entire article:
http://www.bloomberg.com/news/2011-04-02/bristol-myers-interferon-free-combo-cured-hepatitis-c-patients.html

No Comments - be the first!
Share
Share
Previous

Combination Therapy Plus Fluvastatin Improves Hep C Outcome

Back to News Homepage
Next

Telaprevir's Chemistry Speeds HCV Treatment Time

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.